Oncodesign Precision Medicine S.A
ALOPM | Euronext Access Plus
Overview
Corporate Details
- ISIN(s):
- FR001400CM63
- LEI:
- 969500ZDX1IY47LDL876
- Country:
- France
- Address:
- 18 RUE JEAN MAZEN, 21000 DIJON
- Website:
- https://www.oncodesign.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
OPM is a technological company specialized in precision medicine. OPM's mission is to bring innovative therapeutic and diagnostic solutions to treat therapeutic resistance and metastasis evolution. The patient is at the centre of our reflexion, of our unique innovative model, and our investments. For OPM "our collective success is paramount", there can be no value creation without exchange, without dialogue. The value creation resulting for us from reciprocity, i.e. balanced and fair exchanges at all levels, whether between internal collaborators, or with our partners, therapists, patients, experts and investors.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-11 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
|
French | 466.5 KB | |
| 2025-05-06 18:00 |
General Meeting Notice
Informations privilégiées / Autres communiqués
|
French | 216.8 KB | |
| 2025-04-17 18:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 341.8 KB | |
| 2025-04-17 18:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 331.1 KB | |
| 2025-04-03 18:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 364.7 KB | |
| 2025-04-03 18:00 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 379.5 KB | |
| 2025-03-24 18:11 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 540.6 KB | |
| 2025-03-24 18:11 |
Regulatory News Service
Inside Information / Other news releases
|
English | 629.3 KB | |
| 2025-03-04 17:45 |
Board/Management Change
Nomination of Christophe Thurieau as an Independent Member of OPM Board of Dire…
|
French | 293.7 KB | |
| 2025-03-04 17:45 |
Board/Management Change
Nomination of Christophe Thurieau as an Independent Member of OPM Board of Dire…
|
English | 287.9 KB | |
| 2025-01-08 18:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 604.4 KB | |
| 2024-12-20 08:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 296.9 KB | |
| 2024-12-20 08:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 284.3 KB | |
| 2024-10-22 18:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 310.0 KB | |
| 2024-10-22 18:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 312.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ANIMALCARE GROUP PLC | United Kingdom | ANCR | |
|
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
|
Aptahem AB | Sweden | APTA | |
|
Arctic Bioscience | Norway | ABS | |
|
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
|
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
|
AroCell AB | Sweden | AROC | |
|
Arterra Bioscience | Italy | ABS |